Please assess the completion status of the following clinical trial:

Trial Title: Impact of Hepatitis C Therapy and Bone Health

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. HCV antibody and HCV RNA positive~2. HCV Genotype 1a, 1b, or 4~3. Liver staging assessment:~   a. Cirrhosis will be defined by any of the following: i. A liver biopsy prior to day 1 of this study showing cirrhosis (F4) ii. Fibroscan within 12 calendar months of day 1 of this study showing cirrhosis with result \> 12.5 kPa iii. FibroSURE performed during screening with a score \> 0.75 and APRI \> 2 b. Absence of cirrhosis will be defined by any of the following: i. Liver biopsy performed within 24 months of day 1 of this study showing absence of cirrhosis ii. Fibroscan performed within 12 months of day 1 of this study with a result of ≤ 12.5 kPa iii. FibroSURE score ≤ 0.48 and APRI ≤ 1 during screening~4. If HIV co-infected, HAART regimen will consist of two NRTIs (abacavir, tenofovir disoproxil fumarate or tenofovir alafenamide, each in combination with lamivudine or emtricitabine) with one of the following 3rd agents:~   1. raltegravir~  2. dolutegravir~  3. rilpivirine HIV co-infected patients must be on their stable HAART regimen for at least 6 months, with HIV viral load \< 50 c/mL at screening~Exclusion Criteria:~1. Hepatitis B surface antigen positivity~2. Decompensated cirrhosis (Child Pugh B or C)~3. Any prior hepatitis C treatment~4. Pregnant or nursing~5. Treatment with any medication specifically contraindicated with EBR/GZR or not recommended for concomitant use as per the prescribing label (Table 2)~6. Age less than 18~7. Prisoners or subjects otherwise involuntarily incarcerated~8. Absence of signed informed consent by patient or appropriate surrogate~9. Known hypersensitivity to elbasvir or grazoprevir~10. For patients with genotype 1a, one more of the following mutations on baseline NS5A genotype: M28, Q30, L31, or Y93

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- EBR/GZR (Zepatier) - HCV/HIV co-infected (Type: EXPERIMENTAL): Drug: Elbasvir (EBR) 50 mg and Grazoprevir (GZR) 100 mg single tablet by mouth, once daily.
- EBR/GZR (Zepatier) - HCV monoinfected (Type: EXPERIMENTAL): Drug: Elbasvir (EBR) 50 mg and Grazoprevir (GZR) 100 mg single tablet by mouth, once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).